Renier J. Brentjens, MD, PhD
Associate Member, Associate Attending Physician, Leukemia Service & Chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center
Renier J. Brentjens, MD, PhD, obtained an MD and PhD (microbiology) from SUNY Buffalo, completed residency in medicine at Yale New Haven Hospital, and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC).
Currently, Dr. Brentjens is an associate member on the faculty at MSKCC and an attending physician on the leukemia service.
As a medical oncology fellow during his
training at MSKCC
, Dr. Brentjens
initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T cell receptors termed chimeric antigen receptors (CARs).
Following completion of his medical oncology training, Dr. Brentjens became the principal investigator (PI) of his own laboratory.
As a PI, Dr. Brentjens
successfully translated these studies to the clinical setting, treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL).
Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T cells, designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of "armored CAR T cells" currently being translated to the clinical setting as second-generation CAR modified T cell clinical trials.
Additionally, work in Dr. Brentjens'
lab has expanded this CAR technology to target additional tumor antigens expressed on other tumors, including targeting the MUC-16 antigen expressed on ovarian carcinomas as well as the more ubiquitous WT-1 tumor associated antigen.